Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
| Autor: | Eva Kosek, Thomas R. Tölle, Serge Perrot, M. Spath, Juan Antonio Mico, Vladimir Skljarevski, Stefan Wilhelm, Didier Bouhassira, Giorgio Cruccu, Rainer Freynhagen, A. Lenox-Smith, H. Petto, Ernest Choy, Alberto Lledo, Solomon Tesfaye, Paolo Marchettini |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Analgesic Pregabalin Pain 030209 endocrinology & metabolism Duloxetine Hydrochloride Anxiety Hospital Anxiety and Depression Scale 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetic Neuropathies Medicine Duloxetine Humans Depression (differential diagnoses) Aged Psychiatric Status Rating Scales Analgesics business.industry Depression Age Factors Middle Aged Antidepressive Agents Affect Anesthesiology and Pain Medicine Mood Treatment Outcome chemistry Anesthesia Anticonvulsants Female medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European journal of pain (London, England). 20(3) |
| ISSN: | 1532-2149 |
| Popis: | To investigate baseline demographics and disease characteristics as predictors of the analgesic effect of duloxetine and pregabalin on diabetic peripheral neuropathic pain (DPNP).Based on data from the COMBO-DN study, a multinational clinical trial in DPNP, the potential impact of baseline characteristics on pain relief after 8-week monotherapy with 60 mg/day duloxetine or 300 mg/day pregabalin was assessed using analyses of covariance. Subgroups of interest were characterized regarding their baseline characteristics and efficacy outcomes.A total of 804 patients were evaluated at baseline. A significant interaction with treatment was observed in the mood symptom subgroups with a larger pain reduction in duloxetine-treated patients having no mood symptoms [Hospital Anxiety and Depression Scale (HADS) depression or anxiety subscale score11; -2.33 (duloxetine); -1.52 (pregabalin); p = 0.024]. There were no significant interactions between treatment for subgroups by age (65 or ≥65 years), gender, baseline pain severity [Brief Pain Inventory Modified Short Form (BPI-MSF) average pain6 or ≥6], diabetic neuropathy duration (≤2 or2 years), baseline haemoglobin A1c (HbA1c) (8% or ≥8%), presence of comorbidities and concomitant medication use.Our analyses suggest that the efficacy of duloxetine and pregabalin for initial 8-week treatment in DPNP was consistent across examined subgroups based on demographics and disease characteristics at baseline except for the presence of mood symptoms. Duloxetine treatment appeared to be particularly beneficial in DPNP patients having no mood symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text